Molecular Diagnosis & Therapy

, Volume 10, Issue 4, pp 221–230 | Cite as

Molecular Screening of Cancer

The Future is Here


The remarkable growth in our knowledge of the biology of cancer is leading to the identification of previously elusive pathways and networks involved in cancer causation. The development of technologies has played a pivotal role in furthering this understanding and appreciation of the complexity of tumorigenesis, and is advancing efforts to fully grasp the biology and exploit the knowledge for improvements in cancer detection, prevention, and therapy. The future of molecular screening, i.e. detection of risk or cancer via molecular determinants, has never been so close to a reality. Molecular assays employed in cancer detection and therapy are likely to revolutionize cancer treatment through individual-based diagnosis and treatment, i.e. personalized medicine. A number of detection techniques, such as the detection of aberrant DNA and RNA, the presence of auto-antibodies in serum or plasma, and protein profiling, are already in limited use for patient stratification for clinical trials and for predicting drug response.


  1. 1.
    Weir H, Thun M, Hankey B, et al. Annual report to the nation on the status of cancer, 1975–2000. J Natl Cancer Inst 2003; 95(17): 1276–99PubMedCrossRefGoogle Scholar
  2. 2.
    Eyre HJ, Smith RA, Mettlin CJ. Cancer Medicine. 5th ed. Hamilton, Ontario: BC Decker Inc., 2002Google Scholar
  3. 3.
    Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002; 165(4): 508–13PubMedGoogle Scholar
  4. 4.
    Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000 Nov 1; 60(21): 5954–8PubMedGoogle Scholar
  5. 5.
    Campa MJ, Wang MZ, Howard B, et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 2003; 63(7): 1652–6PubMedGoogle Scholar
  6. 6.
    Wagner P, Verma M, Srivastava S. Challenges for biomarkers in cancer detection. New York: New York Academy of Science, 2004Google Scholar
  7. 7.
    Fasouliotis SJ, Schenker JG. BRCA and BRCA2 gene mutations: decision making dilemmas concerning testing and management. Obstet Gynecol Surv 2000; 55(6): 373–84PubMedCrossRefGoogle Scholar
  8. 8.
    Ludwig JA, Weinstein J. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5(11): 845–85PubMedCrossRefGoogle Scholar
  9. 9.
    Feng Z, Prentice R, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistic perspective. Pharmacogenomics 2004; 5(6): 709–19PubMedCrossRefGoogle Scholar
  10. 10.
    Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256(5053): 102–5PubMedCrossRefGoogle Scholar
  11. 11.
    Villa E, Dugani A, Rebecchi AM, et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996; 110(5): 1346–53PubMedCrossRefGoogle Scholar
  12. 12.
    Nollau P, Moser C, Weinland G, et al. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 1996; 66(3): 332–6PubMedCrossRefGoogle Scholar
  13. 13.
    Su YH, Wang M, Aiamkitsumrit B, et al. Detection of a K-ras mutation in urine of patients with colorectal cancer. Disease Markers. In pressGoogle Scholar
  14. 14.
    Umar A, editor. Lynch syndrome (HNPCC) and microsatellite instability. Amsterdam: IOS Press, 2004Google Scholar
  15. 15.
    Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2003; 3(12): 755–62CrossRefGoogle Scholar
  16. 16.
    Ohtani-Fujita N, Dryja TP, Rapaport JM, et al. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet Cytogenet 1997 Oct 1; 98(1): 43–9PubMedCrossRefGoogle Scholar
  17. 17.
    Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92(7): 515–7CrossRefGoogle Scholar
  18. 18.
    Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000; 60(16): 4366–71PubMedGoogle Scholar
  19. 19.
    Battagli C, Uzzo R, Dulaimi E, et al. Tumor suppressor gene hypermethylation in urine DNA from kidney cancer patients. Cancer Res 2003; 63(24): 8695–9PubMedGoogle Scholar
  20. 20.
    Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001; 1(1): 61–7PubMedGoogle Scholar
  21. 21.
    Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004; 10(7): 2284–8PubMedCrossRefGoogle Scholar
  22. 22.
    Dunning AM, Healey CS, Pharoah PD-P, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8(10): 843–54PubMedGoogle Scholar
  23. 23.
    Takakura S, Kohno T, Shimizu K, et al. Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers. Oncogene 2000 Feb 10; 19(6): 836–40PubMedCrossRefGoogle Scholar
  24. 24.
    O’Keefe LV, Richards RI. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett 2006 Jan 28; 232(1): 37–47PubMedCrossRefGoogle Scholar
  25. 25.
    Srinivas PR, Verma M, Zhao Y, et al. Proteomics for cancer biomarker discovery. Clin Chem 2002; 48(8): 1160–9PubMedGoogle Scholar
  26. 26.
    Fung E, Diamond D, Simonsesn AH, et al. The use of SELDI ProteinChip array technology in renal disease research. Methods Mol Med 2003; 86: 295–312PubMedGoogle Scholar
  27. 27.
    Fung ET, Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques 2002 Mar; Suppl. 34-8: 40–1Google Scholar
  28. 28.
    Petricoin EF, Ardekani AM, Hitt BA, et al. Use of serum patterns to identify ovarian cancer. Lancet 2002; 359(9306): 572–7PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64(16): 5882–90PubMedCrossRefGoogle Scholar
  30. 30.
    Vlahou A, Laronga C, Wilson L, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4(3): 203–9PubMedGoogle Scholar
  31. 31.
    Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62(13): 3609–14PubMedGoogle Scholar
  32. 32.
    Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; 3(4): 317–25PubMedCrossRefGoogle Scholar
  33. 33.
    Sreekumar A, Chinnaiyan AM. Protein microarrays: a powerful tool to study cancer. Curr Opin Mol Ther 2002; 4(6): 587–93PubMedGoogle Scholar
  34. 34.
    Miller JC, Zhou H, Kwekel J, et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003; 3(1): 56–63PubMedCrossRefGoogle Scholar
  35. 35.
    Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003; 21(1): 37–8PubMedCrossRefGoogle Scholar
  36. 36.
    Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353(12): 1224–35PubMedCrossRefGoogle Scholar
  37. 37.
    Ransohoff D. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005; 5(2): 142–9PubMedCrossRefGoogle Scholar
  38. 38.
    Ransohoff D. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004; 4(4): 309–14PubMedCrossRefGoogle Scholar
  39. 39.
    Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93(4): 1054–61PubMedCrossRefGoogle Scholar
  40. 40.
    National Cancer Institute Early Detection Research Network [online]. Available from URL: [Accessed 2006 Jun 13]
  41. 41.
    Steiner G, Schoenberg MP, Linn JF, et al. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997; 3(6): 621–4PubMedCrossRefGoogle Scholar
  42. 42.
    Fujiyama S, Izuno K, Gohshi K, et al. Clinical usefulness of des-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 1991; 36(12): 1787–92PubMedCrossRefGoogle Scholar
  43. 43.
    Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprotbrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37(5): 1114–21PubMedCrossRefGoogle Scholar
  44. 44.
    Xie Y, Liu J, Zhang J, et al. Method for the comparative glycomic analyses of O-linked, mucin-type oligosaccharides. Anal Chem 2004; 76(17): 5186–97PubMedCrossRefGoogle Scholar
  45. 45.
    Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005; 83(4): 429–39PubMedCrossRefGoogle Scholar
  46. 46.
    Rudd PM, Elliott T, Cresswell P, et al. Glycosylation and the immune system. Science 2001; 291(5512): 2370–6PubMedCrossRefGoogle Scholar
  47. 47.
    Terasawa K, Furumoto H, Kamada M, et al. Expression of Tn and Sialyl-Tn antigens in the neoplastic transformation of uterine cervical epithelial cells. Cancer Res 1996; 56(9): 2229–32PubMedGoogle Scholar
  48. 48.
    Nakamori S, Furukawa H, Hiratsuka M, et al. Expression of carbohydrate antigen sialyl Le(a): a new functional prognostic factor in gastric cancer. J Clin Oncol 1997; 15(2): 816–25PubMedGoogle Scholar
  49. 49.
    Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A: a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 1991; 324(16): 1084–90PubMedCrossRefGoogle Scholar
  50. 50.
    Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006; 66(9): 4553–7PubMedCrossRefGoogle Scholar
  51. 51.
    National Cancer Institute. The cancer genome atlas [online]. Available from URL: [Accessed 2006 June 14]

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Cancer Biomarkers Research GroupNational Cancer InstituteRockvilleMarylandUSA

Personalised recommendations